273 related articles for article (PubMed ID: 19388880)
1. VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Barakat MR; Kaiser PK
Expert Opin Investig Drugs; 2009 May; 18(5):637-46. PubMed ID: 19388880
[TBL] [Abstract][Full Text] [Related]
2. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.
Mousa SA; Mousa SS
BioDrugs; 2010 Jun; 24(3):183-94. PubMed ID: 20210371
[TBL] [Abstract][Full Text] [Related]
3. Neovascular age-related macular degeneration: potential therapies.
Chappelow AV; Kaiser PK
Drugs; 2008; 68(8):1029-36. PubMed ID: 18484796
[TBL] [Abstract][Full Text] [Related]
4. Promising new treatments for neovascular age-related macular degeneration.
Michels S; Schmidt-Erfurth U; Rosenfeld PJ
Expert Opin Investig Drugs; 2006 Jul; 15(7):779-93. PubMed ID: 16787141
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Ng EW; Adamis AP
Can J Ophthalmol; 2005 Jun; 40(3):352-68. PubMed ID: 15947805
[TBL] [Abstract][Full Text] [Related]
6. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF agents for age-related macular degeneration.
Ozkiris A
Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
[TBL] [Abstract][Full Text] [Related]
9. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
Doggrell SA
Expert Opin Pharmacother; 2005 Jul; 6(8):1421-3. PubMed ID: 16013991
[TBL] [Abstract][Full Text] [Related]
10. [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].
Dyakov IN; Zyryanov SK
Vestn Oftalmol; 2017; 133(2):125-129. PubMed ID: 28524152
[TBL] [Abstract][Full Text] [Related]
11. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
[TBL] [Abstract][Full Text] [Related]
12. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
13. Pegaptanib for the treatment of age-related macular degeneration.
Zhou B; Wang B
Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic approaches in neovascular age-related macular degeneration.
Nguyen DH; Luo J; Zhang K; Zhang M
Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
[TBL] [Abstract][Full Text] [Related]
16. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
17. Association of neovascular age-related macular degeneration with month and season of birth in Italy.
Longo A; Casuccio A; Pani L; Avitabile T; Cillino S; Uva MG; Bonfiglio V; Russo A; Parisi G; Cennamo G; Furino C; Parravano M; Xoxi E; Reibaldi M
Aging (Albany NY); 2016 Dec; 9(1):133-141. PubMed ID: 27997361
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
19. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
20. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
